Tuberculosis drug development hobbles forward
By Erica Lessem Introduction After forty years without new approved drug classes, tuberculosis (TB) treatment has recently advanced with the approval of two new compounds to treat multidrug-resistant...
View ArticleThe tuberculosis diagnostics pipeline
By Colleen Daniels Accurate diagnosis of tuberculosis (TB) is the gateway to treatment and—it is hoped—cure for people with latent TB infection (LTBI) or active TB disease. According to the Stop TB...
View ArticleGlobal update: hepatitis C treatment activism
By Karyn Kaplan and Tracy Swan How can governments and donors effectively address HCV if pharma refuses to drop drug prices? —Paata Sabelashvili, Activist, Georgian Harm Reduction Network Keeping up...
View ArticleHepatitis C pipeline: BONANZA! The gold rush is under way
By Tracy Swan The direct-acting antiviral (DAA) era officially began in late 2013, with approval of the first all-oral treatment for hepatitis C virus (HCV) genotypes 2 and 3. A hefty pipeline will...
View ArticleResearch toward a cure and immune-based and gene therapies
By Richard Jefferys Introduction Research working toward the goal of curing HIV infection has rapidly assumed a central, prioritized role within the overall scientific portfolio. Funding has not...
View ArticlePreventive technologies: antiretroviral and vaccine development
By Tim Horn and Richard Jefferys The U.S. Food and Drug Administration (FDA) approval of co-formulated tenofovir DF and emtricitabine (Truvada) as preexposure prophylaxis (PrEP) has transformed the HIV...
View ArticleThe paediatric antiretroviral pipeline
By Polly Clayden Since last year’s Pipeline Report dolutegravir (DTG) was approved for children aged 12 years and older in the United States and Europe. [1, 2] The approvals for this age group were...
View ArticleFit for purpose: treatment optimisation
By Polly Clayden Since the 2013 Pipeline Report treatment optimization has continued to gain traction. Results from one of the key dose optimization trials ENCORE1—showing a lower dose of efavirenz...
View ArticleThe antiretroviral pipeline
By Tim Horn and Simon Collins Introduction By 2024, antiretroviral treatment (ART) could be as different from that used today as triple therapy in 1997 was from AZT monotherapy in 1987, or as...
View ArticleIntroduction and executive summary
By Polly Clayden and Mark Harrington Introduction Last year we wrote: [Getting] the best drugs to the most people as quickly as possible… requires that the compounds and combination products be:...
View ArticleDedication: Marvin Oscar Shulman
This report is dedicated to Marvin Oscar Shulman, May 17, 1932 to January 15, 2014 A fierce AIDS warrior, principled leader, and beloved friend, Marvin Shulman was an activist’s activist. He dedicated...
View ArticleHTB supplement: 2014 Pipeline Report
Annual review of advances in HIV, HCV and TB: new drugs,strategies and vaccine research
View ArticleThe Tuberculosis Vaccines Pipeline: A New Path to the Same Destination?
By Mike Frick Call it a paradigm shift, a pivot, or a turn – tuberculosis (TB) vaccine research and development (R&D) is entering a period of basic science. After years of focusing on phase II...
View ArticleThe Tuberculosis Diagnostics Pipeline
By Mark Harrington That things just go on like this is the catastrophe. Walter Benjamin [1] Introduction Because of the lack of effective, accessible point-of-care (POC) tests for all forms of...
View ArticleMomentum in the Pediatric Tuberculosis Treatment Pipeline
By Lindsay McKenna Introduction Years of building advocacy and research capacity have finally brought about clinical research for children with tuberculosis (TB). While data gaps and delays between...
View ArticleThe Tuberculosis Treatment Pipeline: Moving Beyond “Making the Most of What...
by Erica Lessem For decades, those living with tuberculosis (TB) and their providers have operated in conditions of scarcity and neglect: inadequate funding for programs and research, aging...
View ArticleNew Drugs, New Strategies: Conquering Hepatitis C with Direct-Acting Antivirals
By Tracy Swan Hepatitis C has to be one of the most grossly miscalculated diseases by governments on the planet. Michel Kazatchkine, UN secretary general’s special envoy on HIV/AIDS in Eastern Europe...
View ArticleResearch Toward a Cure and Immune-Based and Gene Therapies
By Richard Jefferys Introduction The rise to prominence of cure research has continued over the past year, with every major scientific conference on HIV now featuring sessions and presentations on the...
View ArticlePreventive Technologies: Antiretroviral and Vaccine Development
By Tim Horn and Richard Jefferys Though global HIV incidence has declined by an estimated 33% since 2001, more than 2 million people continue to be infected with the virus every year – approximately...
View ArticleThe Pediatric Antiretroviral Pipeline
By Polly Clayden Introduction The big news since the 2014 Pipeline Report is that there is finally a solid form of lopinavir/ritonavir (LPV/r) suitable for infants and young children. On 21 May 2015,...
View ArticleFit for purpose: antiretroviral treatment optimisation
By Polly Clayden The most striking news since the 2014 Pipeline Report is from the START (Strategic Timing of AntiRetroviral Treatment) study. [1] We now have evidence from a large, randomised,...
View ArticleThe Antiretroviral Pipeline
By Simon Collins and Tim Horn Introduction As a global community of people living with HIV, our needs from the antiretroviral (ARV) pipeline have changed considerably over the last 20 years....
View ArticleDedication
This report is dedicated to Tireless Champion of Disadvantaged and Vulnerable People Ana Isabel Charle (1979–2015) and Pioneering HIV Researcher and Activist Joseph Albert Marie “Joep” Lange (1954–2014).
View ArticleHTB supplement: 2015 Pipeline Report
Activist review of latest research into HIV, HCV and TB: drugs for adults and children, dose optimisation, diagnostics, prevention, cure and vaccines...
View Article2016 hepatitis C virus (HCV) update
Mark Harrington, TAG Due to recent transitions in the TAG HCV Project [1], we did not complete a comprehensive update on hepatitis C virus (HCV) pipeline. Here are a few highlights in HCV regulation,...
View ArticleThe paediatric tuberculosis treatment pipeline: beyond pharmacokinetics and...
Lindsay McKenna, TAG Introduction The roster of enrolling and planned pediatric tuberculosis (TB) treatment studies is growing. Emerging results from pharmacokinetics (PK) and safety studies continue...
View ArticleThe tuberculosis treatment pipeline: activity, but no answers
Erica Lessem, TAG In the past year, the development of new tuberculosis (TB) drug candidates experienced some setbacks as well as some wise pruning, with the unexpected suspension of enrollment in...
View ArticleThe tuberculosis prevention pipeline
Mike Frick, TAG After decades of receiving short shrift from most national TB programs and international organizations, tuberculosis (TB) prevention is finally coming into the mainstream. In 2015, the...
View ArticleThe tuberculosis diagnostics pipeline
Erica Lessem, TAG Introduction Over the past decade, several new options for improving TB diagnosis have become available. The past year saw considerably more progress than the previous one. However,...
View ArticleResearch toward a cure and immune-based and gene therapies
Richard Jefferys, TAG Introduction The pursuit of a cure for HIV infection has become a central plank of the overall research portfolio, and this has been officially underpinned by the revised HIV/AIDS...
View ArticlePreventive technologies: antiretroviral and vaccine development
Tim Horn and Richard Jefferys, TAG With the continued rollout and implementation of global, national, and regional HIV incidence targets and timelines, one thing has become abundantly clear: reducing...
View ArticleThe paediatric antiretroviral pipeline
Polly Clayden, HIV i-Base Introduction The development of new antiretroviral drugs and appropriate formulations for children continues to be far too slow. There are now 2.6 million children in need of...
View ArticleFit for purpose: antiretroviral treatment optimisation
Polly Clayden, HIV i-Base Introduction Since the 2015 Pipeline Report global antiretroviral treatment (ART) guidelines have moved to recommending “treat all” HIV positive people. With this...
View ArticleThe antiretroviral pipeline
Tim Horn, TAG, and Simon Collins, HIV i-Base Introduction The year 2016 marks 20 years since combination-based antiretroviral therapy (ART) first demonstrated durable, effective and sustained HIV...
View ArticleExecutive summary – tuberculosis
Tuberculosis diagnostics The year 2015–2016 saw more concrete progress in moving new TB diagnostic tests from research to recommendation by the World Health Organization (WHO) than any year since 2010,...
View ArticleExecutive summary – HIV
Mark Harrington, TAG The antiretroviral pipeline In their chapter on Antiretroviral Treatment in this year’s Pipeline Report [9], Tim Horn and Simon Collins provide a sweeping overview of developments...
View ArticleDedications
This report is dedicated to: Paul Blanchard 1964 – 2016 Paul played a unique role in establishing treatment activism in the UK, challenging doctors to continually update their views and practice with...
View ArticleHTB supplement: 2016 Pipeline Report
Activist review of pipeline research for HIV, HCV and TB
View ArticleAcknowledgments
i-Base thanks the Monument Trust and UNITAID for support for this work. Thanks to the TAG staff, board, and donors for supporting the production of the 2016 Pipeline Report. About HIV i-Base HIV i-Base...
View ArticleFit for purpose (July 2017)
This year’s edition of Fit for purpose has expanded. We include treatment for children as well as adults in our annual review of optimised antiretroviral treatment (ART). We have also included reviews...
View ArticleHIV pipeline 2017 PDFs
Several PDF versions are available for HIV Pipeline 2017: Pipeline 2017 – full version PDF (500 Kb) Pipeline 2017 – summary version PDF (400Kb) Update from IAS 2017 (to come)
View ArticleHIV pipeline 2017: Update from IAS Paris
This page is for the IAS Update of the HIV pipeline 2017 report. • Read the full report • Read the summary report The IAS 2017 conference being held in Paris from 23–26 July will include important new...
View ArticleHIV pipeline 2017: summary version
This page is the summary version of HIV pipeline 2017. (Download PDF) • Read full version. • Read the IAS 2007 update. Simon Collins, HIV i-Base Introduction This has been a lively year for HIV...
View ArticleHIV pipeline 2017: full version
This is the full version of HIV pipeline 2017. (Download PDF) • Read the summary version. • Read IAS 2017 update. Introduction This has been a lively year for HIV research. Even though only one new...
View ArticleIntroduction to HIV pipeline 2017
Latest review of future HIV drugs: and what to watch for at IAS 2017 in Paris
View ArticleHIV pipeline 2018: full version
Simon Collins, HIV i-Base This issue of HTB includes HIV pipeline 2018 as a supplement. The report reviews recently approved and pipeline HIV drugs and is linked to the upcoming i-Base Fit for Purpose...
View ArticleFit for purpose: Antiretroviral treatment optimisation
ART optimisation in low- and middle-income countries (LMICs)
View ArticleHIV pipeline report 2019
Simon Collins, HIV i-Base This is the third year that i-Base has produced the HIV pipeline review as part of our Fit for Purpose report on antiretroviral treatment optimisation. Two versions are...
View ArticleHIV pipeline 2020: new drugs in development – March 2020
Simon Collins, HIV i-Base Two versions of this report are available, both also as PDF files. 1. This full online version includes more information for each drug, with full references. Download full...
View ArticlePipeline report 2021: HIV drugs in development
Simon Collins, HIV i-Base For all the focus and difficulties over COVID-19, this year is still an exciting year for HIV pipeline research. This annual review, produced as an i-Base supplement,...
View Article
